OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-10-20
- Target Recruit Count
- 211
- Registration Number
- NCT01111539
- Locations
- 🇮🇳
Study Site 1, Ahmedabad, Gujarat, India
🇮🇳Study Site 2, Ahmedabad, Gujarat, India
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2023-02-02
- Target Recruit Count
- 740
- Registration Number
- NCT01074294
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2015-11-01
- Target Recruit Count
- 773
- Registration Number
- NCT01052077
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Southwestern Research, Beverly Hills, California, United States
🇺🇸California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2014-09-25
- Target Recruit Count
- 30
- Registration Number
- NCT01009840
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Maryland School of Medicine - Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
Oral Aripiprazole Open-Label Rollover Study
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2013-09-27
- Target Recruit Count
- 85
- Registration Number
- NCT01001702
- Locations
- 🇺🇦
Study site, Kiev, Ukraine
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2014-07-31
- Target Recruit Count
- 207
- Registration Number
- NCT00948090
- Locations
- 🇺🇸
UCSD Medical Center BMT Program, La Jolla, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2015-10-20
- Target Recruit Count
- 459
- Registration Number
- NCT00905307
- Locations
- 🇷🇸
Study Site (1), Belgrade, Serbia
🇷🇸Study Site (2), Belgrade, Serbia
🇷🇴Study Site (3), Bucuresti, Romania
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema
- Conditions
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2017-04-17
- Target Recruit Count
- 84
- Registration Number
- NCT00874497
- Locations
- 🇺🇸
Los Angeles Biomedical Institute, Torrance, California, United States
🇺🇸Pulmonary Disease Specialist/PDS Research, Kissimmee, Florida, United States
🇺🇸Texas Institute of Chest and Sleep Disorders, PA, Houston, Texas, United States
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2013-12-02
- Target Recruit Count
- 64
- Registration Number
- NCT00857818
- Locations
- 🇨🇦
Local Institution, Quebec, Canada
Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
- Conditions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2010-05-07
- Target Recruit Count
- 15
- Registration Number
- NCT00805454